In this era of precision medicine, with the help of biomarkers, immunotherapy has
significantly improved prognosis of many patients with malignant tumor. Deficient mismatch …

Over the past years, several studies have demonstrated that defects in DNA damage
response and repair (DDR) genes are present in a significant proportion of patients with …

Molecular stratification can improve the management of advanced cancers, but requires
relevant tumor samples. Metastatic urothelial carcinoma (mUC) is poised to benefit given a …

Purpose: Cross-resistance renders multiple lines of androgen receptor (AR) signaling
inhibitors increasingly futile in metastatic castration-resistant prostate cancer (mCRPC). We …

Background While response rates to anti-PD1 therapy are low in unselected metastatic
castration resistant prostate cancer (mCRPC) patients, those with inactivating mutations in …

Purpose: DNA damage repair (DDR) defects are common across cancer types and can
indicate therapeutic vulnerability. Optimal exploitation of DDR defects in prostate cancer …

Circulating tumor DNA (ctDNA) enables real-time genomic profiling of cancer without the
need for tissue biopsy. ctDNA-based technology is seeing rapid uptake in clinical practice …

Objective Evidence shows that gene mutation is a significant proportion of genetic factors
associated with prostate cancer. The DNA damage response (DDR) is a signal cascade …

Background Genomic alterations in DNA damage response (DDR) genes are common in
metastatic castration-resistant prostate cancer (mCRPC). Understanding how these genomic …

Background Activating mutations in AKT1 and PIK3CA are undercharacterised in metastatic
castration-resistant prostate cancer (mCRPC), but are linked to activation of …